» Articles » PMID: 31937462

Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Ferric Carboxymaltose in Chinese Patients with Iron-deficiency Anemia

Overview
Journal Clin Ther
Specialty Pharmacology
Date 2020 Jan 16
PMID 31937462
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Iron deficiency (ID) is one of the most commonly known nutritional deficiencies and is considered the primary cause of anemia (iron-deficiency anemia). Ferric carboxymaltose (FCM), an intravenous iron preparation, has been widely used for >10 years for iron-deficiency anemia treatment worldwide because of its many advantages.

Methods: This single-center, open-label, single dose escalation study in Chinese subjects was designed to assess the pharmacokinetic/pharmacodynamic parameters and safety of FCM in this population. The first 12 subjects received a 500-mg dose; after assessing safety data from the first 6 subjects in this cohort, another 12 subjects were assigned to the 1000-mg dose cohort.

Findings: After an infusion of FCM over 15 min, a rapid dose-dependent increase in total serum iron levels was observed with a median T of 30 min following the start of the infusion for both cohorts. The C and AUC for the 1000-mg dose were ~1.8-fold (p = 0.2929) and 2.3-fold (p = 0.0318) those associated with the 500-mg dose, respectively. Mean terminal t values were 12.3 and 10.5 h for the 2 cohorts. The renal elimination of FCM was negligible (<0.1%). Increase in mean serum iron levels and ferritin concentrations showed dose dependency. Iron-binding capacity was transiently well utilized after dosing, as indicated by transferrin saturation >88% with 500-mg FCM and >90% with 1000-mg FCM. Hemoglobin levels did not show significant changes during the 7-day observation period, whereas mean reticulocyte counts significantly increased in both cohorts, suggesting activation of the hematopoietic system. FCM was well tolerated in these Chinese subjects. No new or unexpected treatment-emergent adverse events were attributable to FCM.

Implications: The pharmacokinetic/pharmacodynamic and safety profiles in Chinese subjects seemed comparable to those in white and Japanese populations. ChinaDrugTrials.org.cn identifier: CTR20160863.

Citing Articles

Radiomodulating Properties of Superparamagnetic Iron Oxide Nanoparticle (SPION) Agent Ferumoxytol on Human Monocytes: Implications for MRI-Guided Liver Radiotherapy.

Shurin M, Kirichenko V, Shurin G, Lee D, Crane C, Kirichenko A Cancers (Basel). 2024; 16(7).

PMID: 38610996 PMC: 11011128. DOI: 10.3390/cancers16071318.


Efficacy and Safety of Intravenous Ferric Carboxymaltose Treatment of Iron Deficiency Anaemia in Patients with Corpus Atrophic Gastritis: A Retrospective Study.

Dottori L, Corleone Tsarkov D, Dilaghi E, Pivetta G, Scalamonti S, Ligato I Nutrients. 2023; 15(19).

PMID: 37836482 PMC: 10574262. DOI: 10.3390/nu15194199.


Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia.

Korczowski B, Farrell C, Falone M, Blackman N, Rodgers T Pediatr Res. 2023; 94(4):1547-1554.

PMID: 37208431 PMC: 10589089. DOI: 10.1038/s41390-023-02644-9.


A synchronized approach between emergency department and anemia clinic to intravenous iron treatment for very severe (Hb <7.0 g/dL) and extreme (<5.0 g/dL) iron-deficiency anemia: short-, medium- and long-term efficacy and safety analysis.

Beverina I, Ranzini M Blood Transfus. 2023; 21(3):235-239.

PMID: 36795347 PMC: 10159800. DOI: 10.2450/2023.0199-22.


Efficacy and Safety of Intravenous Ferric Carboxymaltose in Patients with Postoperative Anemia Following Same-Day Bilateral Total Knee Arthroplasty: A Randomized Controlled Trial.

Kim M, Koh I, Choi K, Yang S, In Y J Clin Med. 2021; 10(7).

PMID: 33918110 PMC: 8036569. DOI: 10.3390/jcm10071457.